For recurrent respiratory papillomatosis (RRP), novel gene therapy to jump-start immunity to the human papillomavirus (HPV) that causes it was safe and yielded complete response in many cases ...

The FDA has accepted for Priority Review the BLA for PRGN-2012 for the treatment of adults with recurrent respiratory papillomatosis.

INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today ...

Transcriptional regulation is important. An array of gene promoters in the human papillomavirus (HPV) early region may be actively engaged in transcription of the genome and controlled in response ...

PRGN-2012 is designed to elicit immune responses directed against cells infected with human papillomavirus, or HPV, 6 or HPV 11. PRGN-2012 received Breakthrough Therapy Designation, Orphan Drug ...

Infection with HPV 6 or HPV 11 causes RRP, a lifelong neoplastic disease of the upper and lower respiratory tracts that can be fatal. According to Precigen, some 27,000 U.S. adults have RRP based ...

Precigen has won U.S. Food and Drug Administration priority review for its application seeking approval of its proposed PRGN-2012 gene therapy for adults with recurrent respiratory papillomatosis ...

The clinical-stage company, which is advancing a gene therapy to treat a rare disease called recurrent respiratory papillomatosis ... human papillomavirus, or HPV, can cause benign tumors on ...

for the treatment of adults with recurrent respiratory papillomatosis (RRP). RRP is a rare neoplastic disease caused by an infection with human papillomavirus (HPV) 6 or 11. It is characterized by ...